ArticlePloS one2013
Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 76 citations in OpenAlex.
- miR-338-3p attenuates oxaliplatin resistance in gastric cancer cells via targeting thrombospondin-1.Archives of medical science : AMS · 2026Article
- miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.Cerebellum (London, England) · 2025Article
- Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets-A Review.Current issues in molecular biology · 2023Review
- Variations in Fibrinogen-like 1 (Genes · 2022Article
- CASP9 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Inflammatory Breast Cancer.International journal of analytical chemistry · 2022Article
- Identification of circRNA-miRNA-Immune-Related mRNA Regulatory Network in Gastric Cancer.Frontiers in oncology · 2022Article
- hsa_circ_0001018 promotes papillary thyroid cancer by facilitating cell survival, invasion, GMolecular therapy. Nucleic acids · 2021Article
- Molecular interactions of miR-338 during tumor progression and metastasis.Cellular & molecular biology letters · 2021Review
- Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host microRNA Targeting.International journal of molecular sciences · 2020Article
- Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response.Cancers · 2019Article
- Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy.Cancer letters · 2019Review
- CircHIPK3 overexpression accelerates the proliferation and invasion of prostate cancer cells through regulating miRNA-338-3p.OncoTargets and therapy · 2019Article
- Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers.Pathology oncology research : POR · 2018Review
- MicroRNA-338-3p Suppresses Proliferation of Human Liver Cancer Cells by Targeting SphK2.Oncology research · 2018Article
- Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer.Oncogene · 2018Review
- miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B.Cell death & disease · 2018Article
- MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.International journal of biological sciences · 2018Article
- MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma.Experimental and therapeutic medicine · 2017Article
- miR-338-3p inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma cells.Oncotarget · 2017Article
- miR-338-3p inhibits the invasion of renal cell carcinoma by downregulation of ALK5.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA has been recently recognized as playing a prominent role in tumorigenesis and metastasis. Here, we report that miR-338-3p was epigenetically silenced in gastric cancer, and its down-regulation was significantly correlated with gastric cancer clinicopathological features. Strikingly, restoring miR-338-3p expression in SGC-7901 gastric cancer cells inhibited proliferation, migration, invasion and tumorigenicity in vitro and in vivo, at least partly through inducing apoptosis. Furthermore, we demonstrate the oncogene SSX2IP is a target of miR-338-3p. We propose that miR-338-3p functions as a tumor suppressor in gastric cancer, and the methylation status of its CpG island could serve as a potential diagnostic marker for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.